Age, years; median (range) | 33 (22–40) |
BMI, kg/m2; median (range) | 21.2 (15.9–31.2) |
Nulliparous; n (%) | 36 (92.3%) |
2018 FIGO stage; n (%) | |
IA1 | 3 (7.7%) |
IA2 | 11 (28.2%) |
IB1 | 25 (64.1%) |
Histology; n (%) | |
Squamous | 22 (56.4%) |
Adenocarcinoma | 17 (43.6%) |
Grading; n (%) | |
G1 | 8 (20.5%) |
G2 | 17 (43.6%) |
G3 | 11 (28.2%) |
na | 3 (7.7%) |
Presence of LVSI; n (%) | 15 (38.5%) |
Depth of invasion, mm (14 patients stage IA); median (range) | 4 (1–8) |
Diagnostic procedure; n (%) | |
Conization | 33 (84.6%) |
Cervical biopsy | 4 (10.3%) |
Excision of a polyp | 2 (5.1%) |
Node evaluation; n (%) | |
Lymphadenectomy/number of nodes removed; median (range) | 29 (74.4%)*/26 (10–45) |
Sentinel node procedure/number of nodes removed; median (range) | 10 (25.6%)/3 (2–6) |
Hospital stay, days; median (range) | 2 (1–4) |
*One patient performed completion lymphadenectomy following unilateral mapping.
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; na, not available.;